Clinical Trial Update: Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of vaginal telapristone acetate (Proellex) for uterine fibroids has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• Telapristone acetate (Proellex) (telapristone acetate)

Snippet

Sponsor: Repros Therapeutics Inc. | Conditions: Uterine Fibroids | Phase 2 | Status: COMPLETED | Results posted: 2019-06-14